



# Immedica's partner Actinium announces lomab-B phase 3 SIERRA trial results in patients with TP53 mutation at the EHA 2024 Annual Congress

**Stockholm, June 15, 2024** - Immedica's partner Actinium Pharmaceuticals, Inc. announced results from the Phase 3 SIERRA trial of lomab-B in patients with a TP53 mutation in an oral presentation at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain.

The Phase 3 SIERRA trial enrolled 153 patients with active relapsed or refractory acute myeloid leukemia (r/r AML) and compared outcomes of patients receiving lomab-B and allogeneic haematopoietic stem cell transplantation (alloHSCT) to those of patients receiving physician's choice of care in the control arm. In total, 24% (37/153) of patients in the SIERRA trial had a TP53 mutation, which is usually associated with poor outcomes, 27 of these patients received lomab-B. lomab-B led alloHSCT significantly improved survival outcomes compared to conventional care in this very high-risk patient population with TP53 mutations.

In addition, data on long-term efficacy of lomab-B in the SIERRA trial was also presented, confirming persistent positive overall survival results.

## **Oral presentation**

131I-apamistamab-led allogeneic hematopoietic cell transplant results in improved survival outcomes in r/r aml patients with high-risk TP53 mutations in the randomized phase 3 SIERRA trial.

Dr. Hannah Choe, Assistant Professor of Medicine at Ohio State University and SIERRA trial investigator.

## **Poster Presentation**

Long term efficacy results of the SIERRA trial: a phase 3 study of 131I-apamistamab-led allogeneic hematopoietic cell transplantation versus conventional care in older patients with active, r/r AML

## **About the EHA Annual Congress**

The European Hematology Association (EHA) Congress is the leading annual event for hematology professionals worldwide. Each year, the congress brings together thousands of experts, researchers, and clinicians to discuss the latest advancements in hematology. The EHA Congress serves as a premier platform for the presentation of groundbreaking research, innovative therapies, and clinical best practices.

For more information on the EHA Congress and its initiatives, please visit the official [EHA website](#).

## **About Actinium Pharmaceuticals, Inc.**

Actinium develops Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidate lomab-B (pre-BLA & MAA (EU)) is an induction and conditioning

agent prior to bone marrow transplant. Actinium plans to advance lomab-B for other blood cancers to potentially improve cell and gene therapy outcomes. Actinium holds more than 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

For more information, please visit: <http://www.actiniumpharma.com/>

### **About Immedica**

Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica's capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica's therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.

Immedica was founded in 2018 by the investment company Impilo and Buy-in-Management. Today Immedica employs more than 100 people across Europe and the Middle East.

For more information visit [www.immedica.com](http://www.immedica.com)

### **Immedica contact:**

Linda Holmström  
Head of Communication  
[linda.holmstrom@immedica.com](mailto:linda.holmstrom@immedica.com)  
+ 46 708 73 40 95

Immedica Pharma AB  
Solnavägen 3H  
SE-113 63 Stockholm